Online article for Non-subscribers

Pay per view

Heterocycles has a pay-per-view service for Non-subscribers.
You will be able to directly purchase the full text article through PayPal.
Your purchased Paper can be downloaded after the payment is completed.
An e-mail will be sent the URL to download the paper.
If you have any questions, please contact:

Price: ¥ 4,400 (Yen only)
Period: This Article can be accessed for 7 days.

Paper | Regular issue | Vol 100, No. 3, 2020, pp.418-428
Published online, 26th February, 2020
DOI: 10.3987/COM-20-14216
Synthesis and Evaluation of Diaminopyrimidine Derivatives as Dual Inhibitors of EGFR and SRC for Antitumor Treatment

Longjia Yan,* Yi Le, Dongmei Chen, Yumei Chen, Di Zhang, and Lan Yang

*School of Pharmaceutical Sciences, Guizhou University, 440 Chongyi Building,Guizhou University, Huaxi District, China


In this paper, a series of novel diaminopyrimidine derivatives was designed and synthesized using palladium-catalyzed Buchwald–Hartwig-type heteroarylamination procedure. And then, they were evaluated for antitumor activity in vitro on wild type epidermal growth factor receptor tyrosine kinase (EGFRwt-TK), c-Src and four human cancer cell lines including A549, PC-3, SMMC-7721 and K562. The results displayed that some of the compounds had good activities. Especially 2-(2-cycloheptylamino-5-trifluoromethylpyrimidin-4-ylamino)-N-methylbenzami-de (1h) showed high antitumor activities against four cancer cell lines with 2.33, 7.46, 1.13 and 1.28 μM. Furthermore, the IC50 values of compound 1h for EGFR and Src reached in 0.86 μM and 0.22 μM.